Method for expressing and purifying protein by using csq-tag
US-2024209046-A1 · Jun 27, 2024 · US
EGFR and c-Met fibronectin type III domain binding molecules
US10954284B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10954284-B2 |
| Application number | US-201715637276-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2017 |
| Priority date | Nov 21, 2012 |
| Publication date | Mar 23, 2021 |
| Grant date | Mar 23, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
First claim
Opening claim text (preview).
What is claimed: 1. A protein comprising a peptide having the amino acid sequence of SEQ ID NO: 61. 2. The protein of claim 1 , further comprising a cysteine linked to the C-terminus of the protein. 3. The protein of claim 1 , further comprising a half-life extending moiety coupled to the protein. 4. The protein of claim 3 , wherein the half-life extending moiety is an albumin binding molecule, a polyethylene glycol (PEG), albumin, or at least a portion of an Fc region of an immunoglobulin. 5. A pharmaceutical composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier. 6. A pharmaceutical composition comprising the protein of claim 4 and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
- C07K14/78Primary
Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG] · CPC title
from mammals · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
against receptors, cell surface antigens or cell surface determinants · CPC title
Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10954284B2 cover?
- Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/78. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).